ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · CUV.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Clinuvel Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 46.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Clinuvel Pharmaceuticals Limited’s forward annual dividend is A$0.05 per share, paid annual. The forward yield is 0.69% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Clinuvel Pharmaceuticals Limited’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of A$0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clinuvel Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2024 | Feb 22, 2024 | A$0.21-17.67% vs estimate | A$32.26M-7.31% vs estimate |
|---|
| Q4 2023 | Aug 30, 2023 | A$0.37+0.6% vs estimate | A$48.97M-48.61% vs estimate |
|---|
| Q2 2023 | Feb 23, 2023 | A$0.22-11.08% vs estimate | A$29.36M-9.5% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
A$196.20-A$0.89 (-0.45%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 28.09% below the high.
A$55.60+A$0.68 (+1.24%)
Ramsay Health Care Limited’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
A$19.57+A$0.50 (+2.62%)
Sonic Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 19.37% below the high.
A$143.64+A$1.44 (+1.01%)
Cochlear Limited’s quoted price sits in the lower half of its reported 52-week range, 50.67% below the high.
A$45.44+A$0.32 (+0.71%)
Ansell Limited’s quoted price sits in the upper half of its reported 52-week range, 2.84% below the high.
A$0.01-A$0.00 (-16.67%)
Botanix Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 93.33% below the high.
